Aug. 1 Management tracks: R&D chief leaving Adaptimmune; plus Frontier Medicines builds out team and more

Adrian Rawcliffe, the incoming CEO of Adaptimmune Therapeutics plc (NASDAQ:ADAP), said Rafael Amado is leaving the T cell therapy company as president of R&D, effective Aug. 12, to pursue other opportunities. Rawcliffe also announced the promotion of John Lunger to chief patient supply officer, from SVP, manufacturing and supply chain,

Read the full 504 word article

How to gain access

Continue reading with a
two-week free trial.